Clinical Trials on Cancer-related Cognitive Difficulties in Finland

Total 239 results

Laekna Limited

Active, not recruiting

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II)

Platinum-resistant Ovarian Cancer

United States, China
ImmunoGen, Inc.

Active, not recruiting

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, France, Belgium, Spain, Ireland, Italy, Australia, Canada
Novartis Pharmaceuticals

Completed

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Melanoma | Triple Negative Breast Cancer | Endometrial Carcinoma | Pancreatic Carcinoma

United States, Germany, Italy, Japan, Belgium, Switzerland, Korea, Republic of, Hong Kong, Finland, France, Spain
ImmunoGen, Inc.
Gynecologic Oncology Group

Completed

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

United States, France, Canada, Spain, Switzerland, Belgium, Italy, United Kingdom, Ireland, Russian Federation, Bosnia and Herzegovina, Czechia, Serbia
Pfizer

Terminated

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Low-grade Serous Ovarian Cancer | Low-grade Serous Fallopian Tube Cancer | Low-grade Serous Peritoneal Cancer

United States, Canada, Hungary, Spain, Belgium, France, United Kingdom, Australia, Czechia, Netherlands, Sweden, Italy, Denmark, Germany, Austria, Finland, Ireland, Norway, Poland
Tesaro, Inc.

Active, not recruiting

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Ovarian Neoplasms

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage II Ovarian Cancer AJCC v6 and v7 | Stage IIA Fallopian Tube Cancer AJCC v6 and v7 | Stage IIB Fallopian... and other conditions

United States
Amgen

Terminated

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Austria, Belgium, Italy, Netherlands, Spain, Canada, Denmark, Germany, Korea, Republic of, Russian Federation, Hong Kong, Greece, Japan
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Previously Treated Non-Small Cell Lung Cancer

United States
Bicara Therapeutics
Merck Sharp & Dohme LLC

Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Head and Neck Neoplasms | Carcinoma, Squamous Cell | Colorectal Cancer | Squamous Cell Carcinoma of Head and Neck | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma | Pancreas Cancer | Squamous Cell Carcinoma of the Lung | Cutaneous Squamous Cell Carcinoma | Squamous Cell Carcinoma of... and other conditions

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States, Korea, Republic of, Japan
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass

Ovarian Cancer | Fallopian Tube Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8 | Stage II Fallopian Tube Cancer AJCC v8 | Stage II Ovarian... and other conditions

United States, Canada, Korea, Republic of, Puerto Rico, Ireland
Hospices Civils de Lyon

Completed

EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer (EWOC-1)

Ovarian Cancer

Denmark, Sweden, Finland, Italy, Canada, France
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

Pancreatic Cancer

United States, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Ovarian Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage... and other conditions

United States
OMNI Medical Services, LLC
OMNI Medical Services Inc

Recruiting

Outcomes Mandate National Integration With Cannabis as Medicine (OMNI-Can)

Depression | COVID-19 | Epilepsy | Multiple Sclerosis | Glaucoma | Cancer | Covid19 | Chronic Pain | Parkinson Disease | Inflammatory Bowel Diseases | Hepatitis C | Insomnia | HIV/AIDS | Amyotrophic Lateral Sclerosis | Fibromyalgia | Anxiety | Bipolar Disorder | Seizures | Crohn Disease | Traumatic Brain Injury | Ulcerative Colitis | Sickle... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
Tesaro, Inc.
Myriad Genetics, Inc.; Facing Our Risk of Cancer Empowered

Completed

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA)

Ovarian Neoplasms | Ovarian Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

Melanoma | Malignant Mesothelioma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Gestational Trophoblastic Tumor | Cervical Adenocarcinoma and other conditions

United States
Eisai Inc.

Completed

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Platinum-Sensitive Ovarian Cancer in First Relapse

United States, Italy, United Kingdom, Germany, Spain, Belgium, Japan
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

Fallopian Tube Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Malignant Ovarian Brenner Tumor and other conditions

United States
Arcagy Research
Belgian Gynaecological Oncology Group; Grupo Español de Investigación en Cáncer... and other collaborators

Completed

Platine, Avastin and OLAparib in 1st Line (PAOLA-1)

Ovarian Cancer

France, Germany, Austria, Denmark, Italy, Japan, Finland, Spain, Monaco, Sweden, Belgium
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Mixed Mesodermal (Mullerian) Tumor | Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage... and other conditions

United States, Korea, Republic of
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
NCIC Clinical Trials Group

Completed

ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer

Ovarian Cancer

United States, Canada, United Kingdom
Unither Pharmaceuticals

Terminated

Clinical Trial for Ovarian Cancer (OvaRex®)

Ovarian Cancer

United States
Pfizer

Completed

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Ovarian Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck

United States, Spain
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Active, not recruiting

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian Neoplasms | Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

United States, Netherlands, Spain, Finland, Italy, Poland, Belgium, Canada, France, Germany, Romania, Ukraine, Norway, United Kingdom, Israel, Greece, Denmark, Belarus, Czechia
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7

United States, Canada, Israel, Belgium
Eli Lilly and Company

Completed

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Ovarian Cancer

United States, Israel, Spain, Korea, Republic of, Australia, Belgium, United Kingdom, Italy
Mario Negri Institute for Pharmacological Research
PharmaMar; Averion International Corporation

Completed

INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer (INOVATYON)

Ovarian Cancer

Austria, Belgium, Norway, Spain, Finland, United Kingdom, Italy, Denmark, Germany, Netherlands, Switzerland
Eastern Cooperative Oncology Group

Recruiting

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Melanoma | Breast Cancer, NOS | CNS Primary Tumor, NOS | Cervical Cancer, NOS | Colorectal Cancer, NOS | Leukemia, NOS | Lymphoma, NOS | Miscellaneous Neoplasm, NOS | Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS | Testicular Nonseminomatous Germ Cell Tumor, NOS | Thyroid Cancer, NOS | Bone Cancer, NOS

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Psychological Impact of Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Melanoma | Sarcoma | Acute Myeloid Leukemia | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Stage III Pancreatic... and other conditions

United States
Hoffmann-La Roche

Completed

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Ovarian Cancer

Belgium, Denmark, France, Germany, Portugal, Spain, Turkey, Bosnia and Herzegovina, Italy, Sweden, Finland, Netherlands, Norway, Greece
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT); Myriad... and other collaborators

Active, not recruiting

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

Advanced Ovarian Cancer

Canada, Denmark, Germany, Italy, Spain, United States, Belgium, Poland, France, Korea, Republic of, Brazil, Hungary, Japan, Peru, Turkey, China, Austria, Bulgaria, Finland, Romania
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
National Cancer Institute (NCI)

Completed

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy (S1115)

Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer | Pancreatic Acinar Cell Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Stage I Uterine Corpus Cancer AJCC v8 | Stage II Uterine Corpus Cancer AJCC v8

United States, Puerto Rico
Boehringer Ingelheim

Completed

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Ovarian Neoplasms | Peritoneal Neoplasms

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT); US Oncology... and other collaborators

Completed

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Ovarian Neoplasms | Platinum Sensitive Ovarian Cancer

United States, Belgium, Sweden, Germany, Israel, Austria, Canada, Denmark, Spain, Italy, United Kingdom, Poland, France, Hungary, Norway
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer

Sarcoma | Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Leukemia | Ovarian Cancer | Brain and Central Nervous System Tumors | Neuroblastoma | Liver Cancer | Psychosocial Effects of Cancer and Its Treatment | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

United States, Puerto Rico, Canada, Switzerland
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recurrent Endometrial Endometrioid Adenocarcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Metastatic Endometrial Endometrioid Adenocarcinoma

United States
AGO Research GmbH
Hoffmann-La Roche

Active, not recruiting

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Recurrent Ovarian Carcinoma

Norway, Spain, France, Switzerland, Denmark, Germany, Sweden, Belgium, Finland, Austria, Estonia, Lithuania
National Cancer Institute (NCI)

Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Malignant Solid Neoplasm | Acute Myeloid Leukemia | Multiple Myeloma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer... and other conditions

United States, Puerto Rico
Acrivon Therapeutics
GOG Foundation

Recruiting

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Platinum-resistant Ovarian Cancer | Urothelial Carcinoma | Endometrial Adenocarcinoma

United States
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more

Clinical Trials on Cancer-related Cognitive Difficulties in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations